Cargando…
Temporary increase in circulating replication-competent latent HIV-infected resting CD4+ T cells after switch to an integrase inhibitor based antiretroviral regimen
The principal barrier to an HIV cure is the presence of a latent viral reservoir (LVR) made up primarily of latently infected resting CD4+ (rCD4) T-cells. Studies in the United States have shown that the LVR decays slowly (half-life=3.8 years), but this rate in African populations has been understud...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10246077/ https://www.ncbi.nlm.nih.gov/pubmed/37292785 http://dx.doi.org/10.1101/2023.05.12.23289896 |
_version_ | 1785054972889530368 |
---|---|
author | Ferreira, Roux-Cil Reynolds, Steven J. Capoferri, Adam A. Baker, Owen Brown, Erin E. Klock, Ethan Miller, Jernelle Lai, Jun Saraf, Sharada Kirby, Charles Lynch, Briana Hackman, Jada Gowanlock, Sarah N. Tomusange, Stephen Jamiru, Samiri Anok, Aggrey Kityamuweesi, Taddeo Buule, Paul Bruno, Daniel Martens, Craig Rose, Rebecca Lamers, Susanna L. Galiwango, Ronald M. Poon, Art F. Y. Quinn, Thomas C. Prodger, Jessica L. Redd, Andrew D. |
author_facet | Ferreira, Roux-Cil Reynolds, Steven J. Capoferri, Adam A. Baker, Owen Brown, Erin E. Klock, Ethan Miller, Jernelle Lai, Jun Saraf, Sharada Kirby, Charles Lynch, Briana Hackman, Jada Gowanlock, Sarah N. Tomusange, Stephen Jamiru, Samiri Anok, Aggrey Kityamuweesi, Taddeo Buule, Paul Bruno, Daniel Martens, Craig Rose, Rebecca Lamers, Susanna L. Galiwango, Ronald M. Poon, Art F. Y. Quinn, Thomas C. Prodger, Jessica L. Redd, Andrew D. |
author_sort | Ferreira, Roux-Cil |
collection | PubMed |
description | The principal barrier to an HIV cure is the presence of a latent viral reservoir (LVR) made up primarily of latently infected resting CD4+ (rCD4) T-cells. Studies in the United States have shown that the LVR decays slowly (half-life=3.8 years), but this rate in African populations has been understudied. This study examined longitudinal changes in the inducible replication competent LVR (RC-LVR) of ART-suppressed Ugandans living with HIV (n=88) from 2015–2020 using the quantitative viral outgrowth assay, which measures infectious units per million (IUPM) rCD4 T-cells. In addition, outgrowth viruses were examined with site-directed next-generation sequencing to assess for possible ongoing viral evolution. During the study period (2018–19), Uganda instituted a nationwide rollout of first-line ART consisting of Dolutegravir (DTG) with two NRTI, which replaced the previous regimen that consisted of one NNRTI and the same two NRTI. Changes in the RC-LVR were analyzed using two versions of a novel Bayesian model that estimated the decay rate over time on ART as a single, linear rate (model A) or allowing for an inflection at time of DTG initiation (model B). Model A estimated the population-level slope of RC-LVR change as a non-significant positive increase. This positive slope was due to a temporary increase in the RC-LVR that occurred 0–12 months post-DTG initiation (p<0.0001). This was confirmed with model B, which estimated a significant decay pre-DTG initiation with a half-life of 7.7 years, but a significant positive slope post-DTG initiation leading to a transient estimated doubling-time of 8.1 years. There was no evidence of viral failure in the cohort, or consistent evolution in the outgrowth sequences associated with DTG initiation. These data suggest that either the initiation of DTG, or cessation of NNRTI use, is associated with a significant temporary increase in the circulating RC-LVR. |
format | Online Article Text |
id | pubmed-10246077 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cold Spring Harbor Laboratory |
record_format | MEDLINE/PubMed |
spelling | pubmed-102460772023-06-08 Temporary increase in circulating replication-competent latent HIV-infected resting CD4+ T cells after switch to an integrase inhibitor based antiretroviral regimen Ferreira, Roux-Cil Reynolds, Steven J. Capoferri, Adam A. Baker, Owen Brown, Erin E. Klock, Ethan Miller, Jernelle Lai, Jun Saraf, Sharada Kirby, Charles Lynch, Briana Hackman, Jada Gowanlock, Sarah N. Tomusange, Stephen Jamiru, Samiri Anok, Aggrey Kityamuweesi, Taddeo Buule, Paul Bruno, Daniel Martens, Craig Rose, Rebecca Lamers, Susanna L. Galiwango, Ronald M. Poon, Art F. Y. Quinn, Thomas C. Prodger, Jessica L. Redd, Andrew D. medRxiv Article The principal barrier to an HIV cure is the presence of a latent viral reservoir (LVR) made up primarily of latently infected resting CD4+ (rCD4) T-cells. Studies in the United States have shown that the LVR decays slowly (half-life=3.8 years), but this rate in African populations has been understudied. This study examined longitudinal changes in the inducible replication competent LVR (RC-LVR) of ART-suppressed Ugandans living with HIV (n=88) from 2015–2020 using the quantitative viral outgrowth assay, which measures infectious units per million (IUPM) rCD4 T-cells. In addition, outgrowth viruses were examined with site-directed next-generation sequencing to assess for possible ongoing viral evolution. During the study period (2018–19), Uganda instituted a nationwide rollout of first-line ART consisting of Dolutegravir (DTG) with two NRTI, which replaced the previous regimen that consisted of one NNRTI and the same two NRTI. Changes in the RC-LVR were analyzed using two versions of a novel Bayesian model that estimated the decay rate over time on ART as a single, linear rate (model A) or allowing for an inflection at time of DTG initiation (model B). Model A estimated the population-level slope of RC-LVR change as a non-significant positive increase. This positive slope was due to a temporary increase in the RC-LVR that occurred 0–12 months post-DTG initiation (p<0.0001). This was confirmed with model B, which estimated a significant decay pre-DTG initiation with a half-life of 7.7 years, but a significant positive slope post-DTG initiation leading to a transient estimated doubling-time of 8.1 years. There was no evidence of viral failure in the cohort, or consistent evolution in the outgrowth sequences associated with DTG initiation. These data suggest that either the initiation of DTG, or cessation of NNRTI use, is associated with a significant temporary increase in the circulating RC-LVR. Cold Spring Harbor Laboratory 2023-05-16 /pmc/articles/PMC10246077/ /pubmed/37292785 http://dx.doi.org/10.1101/2023.05.12.23289896 Text en https://creativecommons.org/publicdomain/zero/1.0/This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license (https://creativecommons.org/publicdomain/zero/1.0/) . |
spellingShingle | Article Ferreira, Roux-Cil Reynolds, Steven J. Capoferri, Adam A. Baker, Owen Brown, Erin E. Klock, Ethan Miller, Jernelle Lai, Jun Saraf, Sharada Kirby, Charles Lynch, Briana Hackman, Jada Gowanlock, Sarah N. Tomusange, Stephen Jamiru, Samiri Anok, Aggrey Kityamuweesi, Taddeo Buule, Paul Bruno, Daniel Martens, Craig Rose, Rebecca Lamers, Susanna L. Galiwango, Ronald M. Poon, Art F. Y. Quinn, Thomas C. Prodger, Jessica L. Redd, Andrew D. Temporary increase in circulating replication-competent latent HIV-infected resting CD4+ T cells after switch to an integrase inhibitor based antiretroviral regimen |
title | Temporary increase in circulating replication-competent latent HIV-infected resting CD4+ T cells after switch to an integrase inhibitor based antiretroviral regimen |
title_full | Temporary increase in circulating replication-competent latent HIV-infected resting CD4+ T cells after switch to an integrase inhibitor based antiretroviral regimen |
title_fullStr | Temporary increase in circulating replication-competent latent HIV-infected resting CD4+ T cells after switch to an integrase inhibitor based antiretroviral regimen |
title_full_unstemmed | Temporary increase in circulating replication-competent latent HIV-infected resting CD4+ T cells after switch to an integrase inhibitor based antiretroviral regimen |
title_short | Temporary increase in circulating replication-competent latent HIV-infected resting CD4+ T cells after switch to an integrase inhibitor based antiretroviral regimen |
title_sort | temporary increase in circulating replication-competent latent hiv-infected resting cd4+ t cells after switch to an integrase inhibitor based antiretroviral regimen |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10246077/ https://www.ncbi.nlm.nih.gov/pubmed/37292785 http://dx.doi.org/10.1101/2023.05.12.23289896 |
work_keys_str_mv | AT ferreirarouxcil temporaryincreaseincirculatingreplicationcompetentlatenthivinfectedrestingcd4tcellsafterswitchtoanintegraseinhibitorbasedantiretroviralregimen AT reynoldsstevenj temporaryincreaseincirculatingreplicationcompetentlatenthivinfectedrestingcd4tcellsafterswitchtoanintegraseinhibitorbasedantiretroviralregimen AT capoferriadama temporaryincreaseincirculatingreplicationcompetentlatenthivinfectedrestingcd4tcellsafterswitchtoanintegraseinhibitorbasedantiretroviralregimen AT bakerowen temporaryincreaseincirculatingreplicationcompetentlatenthivinfectedrestingcd4tcellsafterswitchtoanintegraseinhibitorbasedantiretroviralregimen AT brownerine temporaryincreaseincirculatingreplicationcompetentlatenthivinfectedrestingcd4tcellsafterswitchtoanintegraseinhibitorbasedantiretroviralregimen AT klockethan temporaryincreaseincirculatingreplicationcompetentlatenthivinfectedrestingcd4tcellsafterswitchtoanintegraseinhibitorbasedantiretroviralregimen AT millerjernelle temporaryincreaseincirculatingreplicationcompetentlatenthivinfectedrestingcd4tcellsafterswitchtoanintegraseinhibitorbasedantiretroviralregimen AT laijun temporaryincreaseincirculatingreplicationcompetentlatenthivinfectedrestingcd4tcellsafterswitchtoanintegraseinhibitorbasedantiretroviralregimen AT sarafsharada temporaryincreaseincirculatingreplicationcompetentlatenthivinfectedrestingcd4tcellsafterswitchtoanintegraseinhibitorbasedantiretroviralregimen AT kirbycharles temporaryincreaseincirculatingreplicationcompetentlatenthivinfectedrestingcd4tcellsafterswitchtoanintegraseinhibitorbasedantiretroviralregimen AT lynchbriana temporaryincreaseincirculatingreplicationcompetentlatenthivinfectedrestingcd4tcellsafterswitchtoanintegraseinhibitorbasedantiretroviralregimen AT hackmanjada temporaryincreaseincirculatingreplicationcompetentlatenthivinfectedrestingcd4tcellsafterswitchtoanintegraseinhibitorbasedantiretroviralregimen AT gowanlocksarahn temporaryincreaseincirculatingreplicationcompetentlatenthivinfectedrestingcd4tcellsafterswitchtoanintegraseinhibitorbasedantiretroviralregimen AT tomusangestephen temporaryincreaseincirculatingreplicationcompetentlatenthivinfectedrestingcd4tcellsafterswitchtoanintegraseinhibitorbasedantiretroviralregimen AT jamirusamiri temporaryincreaseincirculatingreplicationcompetentlatenthivinfectedrestingcd4tcellsafterswitchtoanintegraseinhibitorbasedantiretroviralregimen AT anokaggrey temporaryincreaseincirculatingreplicationcompetentlatenthivinfectedrestingcd4tcellsafterswitchtoanintegraseinhibitorbasedantiretroviralregimen AT kityamuweesitaddeo temporaryincreaseincirculatingreplicationcompetentlatenthivinfectedrestingcd4tcellsafterswitchtoanintegraseinhibitorbasedantiretroviralregimen AT buulepaul temporaryincreaseincirculatingreplicationcompetentlatenthivinfectedrestingcd4tcellsafterswitchtoanintegraseinhibitorbasedantiretroviralregimen AT brunodaniel temporaryincreaseincirculatingreplicationcompetentlatenthivinfectedrestingcd4tcellsafterswitchtoanintegraseinhibitorbasedantiretroviralregimen AT martenscraig temporaryincreaseincirculatingreplicationcompetentlatenthivinfectedrestingcd4tcellsafterswitchtoanintegraseinhibitorbasedantiretroviralregimen AT roserebecca temporaryincreaseincirculatingreplicationcompetentlatenthivinfectedrestingcd4tcellsafterswitchtoanintegraseinhibitorbasedantiretroviralregimen AT lamerssusannal temporaryincreaseincirculatingreplicationcompetentlatenthivinfectedrestingcd4tcellsafterswitchtoanintegraseinhibitorbasedantiretroviralregimen AT galiwangoronaldm temporaryincreaseincirculatingreplicationcompetentlatenthivinfectedrestingcd4tcellsafterswitchtoanintegraseinhibitorbasedantiretroviralregimen AT poonartfy temporaryincreaseincirculatingreplicationcompetentlatenthivinfectedrestingcd4tcellsafterswitchtoanintegraseinhibitorbasedantiretroviralregimen AT quinnthomasc temporaryincreaseincirculatingreplicationcompetentlatenthivinfectedrestingcd4tcellsafterswitchtoanintegraseinhibitorbasedantiretroviralregimen AT prodgerjessical temporaryincreaseincirculatingreplicationcompetentlatenthivinfectedrestingcd4tcellsafterswitchtoanintegraseinhibitorbasedantiretroviralregimen AT reddandrewd temporaryincreaseincirculatingreplicationcompetentlatenthivinfectedrestingcd4tcellsafterswitchtoanintegraseinhibitorbasedantiretroviralregimen |